A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention and Interception aacrjournals.org/cancerdiscov...

#PRESS: In 2025, we accomplished significant milestones together; we…

👉 reached more patients with our therapies than ever before
👉 invested a record EUR 6.4 bn in R&D
👉 made strong progress across Human Pharma & Animal Health with new launches and vaccines

🧪➡️ go.boehringer.com/1HN8D

Boehringer doubles down on OpenProtein.AI antibody discovery pact
firstwordpharma.com/story/7156470

Honored to share my journey from @embl.org PhD student to bringing new cancer drugs to patients, while working at
Boehringer Ingelheim.
Grateful and proud to be part of the amazing #EMBL family.

NSCLC Precision Oncology - Clinical Edge Issue 6 Precision oncology is reshaping how we understand and treat non-small cell lung cancer (NSCLC). Vicky Brown and Norbert Kraut of Boehringer Ingelheim discuss the science behind today’s targeted therap...

Delighted to be featured in the latest issue of Xtalks Clinical Edge. With my colleague Vicky Brown, we cover advances and opportunities in treating non-small cell lung cancer (NSCLC) patients with precision oncology therapies. Big thanks to the XTalks team!

clinicaledge.xtalks.com/magazine/iss...

Neues Lungenkrebsmittel aus Wien Ein in Wien entwickeltes Medikament gegen eine spezielle Form von Lungenkrebs zeigt vielversprechende Ergebnisse. Nach Zulassungen in den USA, China und Japan könnte es bald auch in Europa verfügbar s...

wien.orf.at/stories/3324...

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer The allele-agnostic mutant-KRAS inhibitor panKRASi inhibits the growth of murine and human pancreatic cancer and promotes antitumor immunity.

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer | Science Translational Medicine
Congrats @anirbanmaitra.bsky.social and @mdanderson.bsky.social @boehringerglobal.bsky.social teams
www.science.org/doi/10.1126/...

ICYMI last year in Cancer Discovery @aacrjournals.bsky.social: Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-driven Cancers – by Birgit Wilding, Ralph Neumüller, et al. doi.org/10.1158/2159...

Minisyposium on "Degraders and Glues" at #AACR25 co-chaired by Rima Al-awar and me this Tuesday, April 29, 2:30 pm CDT:
Hear about new degraders and molecular glues targeting #ALK, #CDK2, #KRAS, #TEAD, #AuroraA and #IKZF2
@theaacr.bsky.social

www.abstractsonline.com/pp8/#!/20273...

Tackling Cancer through Global Team Science #cancergrandchallenges @theaacr.bsky.social aacrjournals.org/cancerdiscov...

Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small Molecule Reactivator Abstract. Restoration of the tumor suppressor function of tumor-associated p53 mutants, including the Y220C substitution, has posed a significant challenge for therapeutic discovery. Here, we describe...

aacrjournals.org/cancerdiscov...

Starting soon @helloeacr.bsky.social

eacr.org/conference/b...

Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers Zongertinib, a covalent HER2 inhibitor, is active in HER2-driven preclinical models and patients and effectively targets HER2 oncogenic signaling while sparing wild-type EGFR, resulting in potent inhi...

Excited to see our paper in print in Cancer Discovery @theaacr.bsky.social
@elizsmckenna.bsky.social
aacrjournals.org/cancerdiscov...

KRAS inhibitors: resistance drivers and combinatorial strategies: Trends in Cancer cell.com/trends/cance...

Hot off the press: Our work with #KRASmulti inhibitors suggests novel therapeutic concept for #cancers harboring #KRAS amplifications. Just published by our team at Boehringer Ingelheim in @theaacr.bsky.social journal Molecular Cancer Therapeutics.
aacrjournals.org/mct/article/...

A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer Exploitation of extrinsic apoptosis signaling via TRAILR2 activation represents a promising therapeutic concept in cancer treatment. The limited clinical success of previous TRAILR2 agonistic agent...

Out now:
Preclinical studies on a new bispecific antibody from the ongoing Boehringer Ingelheim @mdanderson.bsky.social
collaboration:
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive #PancreaticCancer

www.tandfonline.com/doi/10.1080/...

Thanks Anirban for including me

Great story @obenaufa.bsky.social and team. Congrats to a wonderful paper in @natureportfolio.bsky.social